SOPHiA GENETICS SA (SOPH)
| Previous Close | 5.06 |
| Open | 5.13 |
| Bid | 4.93 x 100 |
| Ask | 5.10 x 100 |
| Day's Range | 4.96 - 5.13 |
| 52 Week Range | 2.13 - 7.37 |
| Volume | |
| Avg. Volume | 59,622 |
| Market Cap | 330.425M |
| Beta (5Y Monthly) | 1.17 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.22 |
| Earnings Date | May 07, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 8.67 |
GlobeNewswireSOPHiA GENETICS to Announce Financial Results for First Quarter 2024 on May 7, 2024
BOSTON and ROLLE, Switzerland, April 23, 2024 (GLOBE NEWSWIRE) -- SOPHiA GENETICS, a cloud-native software company and a leader in data-driven medicine, today announced it will release its financial results for the first quarter of fiscal year 2024 before U.S. markets open on Tuesday, May 7, 2024. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m. (08:00) EDT / 2:00 p.m. (14:00) CET. The call will be webcas
PR NewswireSOPHiA GENETICS Announces Syndicate Bio as First Liquid Biopsy Customer in Africa
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced that Nigeria-based Syndicate Bio has signed on to implement MSK-ACCESS® powered with SOPHiA DDM™. Syndicate Bio is the first lab in Africa to adopt the MSK-ACCESS® assay via the SOPHiA DDM™ Platform, and the first company to make comprehensive genomic profiling and liquid biopsy widely available to patients throughout the entire continent. The implementati
Simply Wall St.We Think SOPHiA GENETICS (NASDAQ:SOPH) Can Afford To Drive Business Growth
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
